Leo Labs patents expiration
1. Picato patents expiration
PICATO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9833429 | LEO LABS | Therapeutic compositions |
Dec, 2026
(3 years from now) | |
| US8372828 | LEO LABS | Therapeutic compositions |
Dec, 2026
(3 years from now) | |
| US8536163 | LEO LABS | Therapeutic compositions |
Dec, 2026
(3 years from now) | |
| US8716271 | LEO LABS | Therapeutic compositions |
Dec, 2026
(3 years from now) | |
| US9820959 | LEO LABS | Therapeutic compositions |
Dec, 2026
(3 years from now) | |
| US8735375 | LEO LABS | Therapeutic compositions |
Dec, 2026
(3 years from now) | |
| US9861603 | LEO LABS | Therapeutic compositions |
Dec, 2026
(3 years from now) | |
| US8377919 | LEO LABS | Therapeutic compositions |
Dec, 2026
(3 years from now) | |
| US9833428 | LEO LABS | Therapeutic compositions |
Dec, 2026
(3 years from now) | |
| US8372827 | LEO LABS | Therapeutic compositions |
Dec, 2026
(3 years from now) | |
| US8278292 | LEO LABS | Therapeutic compositions |
Jul, 2027
(3 years from now) | |
| US9789078 | LEO LABS | Method of topically treating actinic keratosis with ingenol mebutate cycle therapy |
May, 2033
(9 years from now) | |
Drugs and Companies using INGENOL MEBUTATE ingredient
Market Authorisation Date: 23 January, 2012
Treatment: Use of ingenol mebutate to treat actinic keratosis; Topical treatment of actinic keratosis of the face or scalp using more than one treatment course of ingenol mebutate
Dosage: GEL;TOPICAL
How can I launch a generic of PICATO before it's drug patent expiration?
More Information on Dosage
PICATO family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic